RxDoctor Payments Data

Kara Brooks, MD

Family Medicine · Crestview, FLNPI 1942441795

Payments from drug & device makers

$503in general payments, 2019–2025

Across 45 payments — averaging $11.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$175
  • Novo Nordisk$145
  • Merck$32
  • Amarin Pharma, Inc.$31
  • Sanofi$28
  • Novartis$27
  • plus $64 from 3 others

What the payments were for

  • Food & beverage$49498%
  • Education$82%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC21$175
Novo Nordisk12$145
Merck2$32
Amarin Pharma, Inc.2$31
Sanofi1$28
Novartis2$27
AstraZeneca2$27
GSK2$25
AbbVie1$12

How this compares

$503 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$81,020
Medicare patients
325
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide82$112,088
OzempicSemaglutide101$107,454
MounjaroTirzepatide76$102,677
JardianceEmpagliflozin64$68,814
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$46,979
EliquisApixaban45$32,248
RybelsusSemaglutide22$28,918
Breo ElliptaFluticasone/Vilanterol21$16,951
MyrbetriqMirabegron25$15,934
JanuviaSitagliptin Phosphate18$14,697
TradjentaLinagliptin16$11,620
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$9,203
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$9,146
Duloxetine Hcl119$5,915
LivaloPitavastatin Calcium15$4,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$175$214,765158 claims
Novo NordiskOzempic, Rybelsus$145$136,372123 claims
GSKTrelegy Ellipta, Breo Ellipta$25$63,93060 claims
MerckJanuvia$32$14,69718 claims
AbbVieSynthroid$12$4,85764 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Crestview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →